IL6 and COVID-19: Recent studies have highlighted a strong association between proinflammatory mediators—particularly interleukin-6 (IL-6)—and coagulation pathways, indicating a shared pathophysiological axis that contributes to thromboinflammatory responses in severe conditions such as COVID-19 and systemic inflammation [3,4].